Innovation and Market Growth in Brazil
The pharmaceutical market in Brazil has been growing steadily and strongly in the past five years. The country is eying production and innovation, relying on the key support of the government. According to industry associations, biopharmaceutical innovation in Brazil will increase in the future as the country starts facing its challenges and participating globally with local and multinational companies.
According to Abifina, Brazil’s Fine Chemicals, Biotechnology, and Specialty Industries Association, Latin American countries are still planting seeds to develop and compete in the global biopharmaceutical market. Brazil, however, plays a key role in the sector with a series of universities and institutes promoting research and development actions, a public health system capable of sustaining part of the local pharmaceutical industry, and a large consumer population at more than 200 million Brazilians.
Market growth in Brazil
According to Mussolini, citing IMS Health figures for the past five years, Brazil’s growth is considered relevant if compared with data for Europe and the US, whose growth levels were around 1%. Mussolini says that the increase is especially due to the fact that the local job market has heated in the past five years and has been transforming the lower classes into active consumers of goods and services. The country’s impact, however, within the biological products market is limited to production and sales and does not necessarily include relevant innovations, according to Reinaldo Guimarães, intellectual property director of Abifina.
“Our increase of the biopharmaceuticals market share is mainly a result of public investments for the government’s health system,” Guimarães told Pharmaceutical Technology. The government is acting as a main buyer, currently responsible for as much as 25% to 30%, with an estimated participation reaching as much as 50% in the next few years, according to Guimarães. The government is establishing key partnerships with local and multinational, private, and public companies, and is funding local production capacity expansions for public and private companies. Brazil is also controlling the efficacy and safety of pharmaceutical products through market regulation.
According to Guimarães, considering government expenditures with health products, biopharmaceuticals correspond to only 5% in terms of units sold and as much as 40% in terms of sales.
“The government is definitely investing on the development of the local biopharmaceutical sector through partnerships and by obtaining technology,” says Mussolini.
According to Sindusfarma’s executive president, however, companies face challenges to become profitable and still lack large production scales. It seems that Brazil-based companies seek to increase production scales and profitability, while government seeks less dependence on imports and a stronger local market, establishing a strong pharmaceutical partnership intended for growth.
With the economy still under control and regulation equivalent to those of developed nations, challenges now lie within high taxes and costs as well as strict price controls, according to Mussolini. Such issues impact profitability and affect future R&D actions as well as most companies’ long-term survival.
“Brazil competes globally in terms of market share …however, to become a global competitor in terms of new products or better products we still have issues to face,” adds the official. In terms of R&D, for example, challenges are attributed to the country’s lack of technological capacity to produce relevant innovation, says Guimarães.
The Brazilian government through its Health Ministry has the goal of substituting imports for locally produced products by establishing technology transfer deals. Such measures have traditionally been used for vaccines and most recently for synthetic drugs as well as biopharmaceutical products.
“I personally believe those estimates to be very optimistic, however, we are indeed heading in the direction of a 12% growth, which would include Brazil in the fifth position …,” says Mussolini.
Nonetheless, “I am sure IMS Health knows exactly what they are saying,” adds Mussolini. “I believe there are no reasons for serious concerns,” concludes Guimarães.
About the Author
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety